Researchers at the University of Michigan have developed a new tool that could revolutionize how doctors track the effectiveness of cancer treatments.
By using a special chip to analyze blood samples, they can now detect the number of cancer cells in a patient’s bloodstream as early as the fourth week of treatment.
This advancement offers a promising new way to personalize cancer care, allowing treatments to be adjusted based on real-time feedback about how well they’re working.
For a long time, assessing the success of cancer treatments has been a waiting game, often requiring weeks or months to determine if the treatment is making a difference.
According to Shruti Jolly, M.D., a leading figure in the study, traditional methods like CT scans and tumor biopsies have their limitations.
Scans can only show significant changes in tumor size, while biopsies, though accurate, cannot be performed frequently enough to provide ongoing updates on a patient’s condition.
This is where liquid biopsies come into play. They involve testing the patient’s blood for signs of cancer, such as cells shed by tumors.
While these tests offer a less invasive way to monitor cancer, their effectiveness depends on the presence of enough cancer cells in the blood to be detectable.
The new chip developed by the University of Michigan team, known as the “GO chip,” overcomes this challenge by using graphene oxide sheets coated with antibodies that capture a wide range of cancer cell markers.
As blood passes through the chip, cancer cells are trapped, allowing for detailed analysis.
This technology is particularly significant for lung cancer patients. Current FDA-approved methods for detecting cancer cells in blood samples have been ineffective for lung cancer, largely because they target a single protein marker that is less common in lung cancers.
The GO chip’s ability to trap cancer cells based on a variety of markers makes it a powerful tool for monitoring how lung cancer responds to treatment.
In a study involving 26 patients undergoing treatment for stage III lung cancer, the researchers used the GO chip to track the number of cancer cells in the blood over time.
They found that a decrease in cancer cells by at least 75% by the fourth week of treatment was a good indicator that the treatment was effective.
Furthermore, the study identified specific genes in cancer cells from patients who did not respond to treatment.
These genes, which may contribute to the cancer’s resistance to therapy, could be potential targets for new treatments.
This chip represents a significant step forward in cancer diagnostics.
By providing early and accurate information about the effectiveness of treatment, it can help avoid the prolonged use of therapies that are not working, sparing patients from unnecessary side effects and potentially improving outcomes.
As research continues, the hope is that this technology will lead to more personalized and effective cancer treatment strategies, making a real difference in the lives of those battling this disease.
If you care about cancer, please read studies about a new method to treat cancer effectively, and this low-dose, four-drug combo may block cancer spread.
For more information about cancer prevention, please see recent studies about nutrient in fish that can be a poison for cancer, and results showing this daily vitamin is critical to cancer prevention.
Copyright © 2024 Knowridge Science Report. All rights reserved.
